Poster Abstract Session:
076. Treatment of Resistant Infections - Clinical Analyses
Thursday, October 5, 2017: 12:30 PM-2:00 PM
Room: Poster Hall CD


Presentations:
776
Comparative effectiveness of Trimethoprim-Sulfamethoxazole vs. Levofloxacin for Stenotrophomonas maltophilia Bacteremia: Analysis of targeted therapy at 90 US Hospitals, 2000-2014
Yi Ling Lai, MPH; Jennifer Adjemian, PhD; Emily Ricotta, PhD, ScM; John P. Dekker, M.D., Ph.D.; Robert L. Danner, MD; Sameer S. Kadri, MD, MS
777
Combination Vancomycin/Cefazolin (VAN/CFZ) for Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infections (BSI)
Trang D. Trinh, PharmD, MPH, BCPS, AAHIVP; Evan J. Zasowski, PharmD, MPH, BCPS; Abdalhamid M. Lagnf, MPH; Sahil Bhatia, B.S.; Sorabh Dhar, MD; Ryan Mynatt, PharmD; Jason M. Pogue, PharmD; Michael J. Rybak, PharmD, MPH, PhD
778
Modeling Likelihood of Coverage for Narrow Spectrum Antibiotics in Patients Hospitalized with Urinary Tract Infections
Courtney Hebert, MD, MS; Erinn Hade, PhD; Protiva Rahman, BS; Mark Lustberg, MD, PhD; Kurt Stevenson, MD, MPH, FSHEA; Preeti Pancholi, PhD
779
Therapeutic efficacy of isavuconazole in experimental Aspergillus fumigatus endophthalmitis
John Guest, BS; Pawan Kumar Singh, Ph.D.; Sanjay G. Revankar, MD; Pranatharthi H. Chandrasekar, MD; Ashok Kumar, Ph.D.
781
Pharmacokinetic Assessment of Continuous Infusion Ceftolozane/Tazobactam for Drug-Resistant Pseudomonas aeruginosa Left Ventricular Assist Device Driveline Infection
Rachel Foster, PharmD, MBA; Alyssa P. Gould, PharmD; Julie Ann Justo, PharmD, MS, BCPS-AQ ID; Stella Okoye, MD; David P. Nicolau, PharmD, FCCP, FIDSA; P. Brandon Bookstaver, PharmD, FCCP, FIDSA, BCPS, AAHIVP
782
Antimicrobial resistance patterns of colonizing Streptococcus pneumoniae among young child-mother pairs in the rural highlands of the Peruvian Andes
Leigh Howard, MD, MPH; Kathryn Edwards, MD, FIDSA; Marie Griffin, MD, MPH; Ana Gil, MS; Gina Minaya, Licensed auxiliary nurse; Erik Mercado, BS; Theresa Ochoa, MD; Claudio Lanata, MD, MPH; Carlos G. Grijalva, MD, MPH
783
Associations Between Timeliness of Therapy and Clinical and Economic Outcomes Among Patients With Serious Infections Due to Gram-negative Bacteria (GNB): How Much Does Delayed Appropriate Therapy (DAT) Matter?
Nicole G. Bonine, PhD, MPH; Ariel Berger, MPH; Arman Altincatal, MS; Rosa Wang, MHA; Tarun Bhagnani, MS; Patrick Gillard, PharmD; Thomas Lodise, PharmD, PhD
786
Effect of Generic vs. Brand-Name Meropenem on Mortality in a Colombian Hospital’s Intensive Care Unit
Max Feinstein, BA; Karen Ordóñez, MD; Sergio Reyes, MD; Christian Pallares, MD, MSc; Cristhian Hernández-Gómez, MSc; Maria Virginia Villegas, MD, MSc, FIDSA
787
Echinocandin Resistant Candida tropicalis Bloodstream Infections
Maroun Sfeir, MD, MPH; Cristina Jiménez-Ortigosa, PhD; Audrey Schuetz, MD; Stephen Jenkins, PhD; Sian Jones, MD; Rosemary Soave, MD, FIDSA; Koen Van Besien, MD, PhD; Michael Satlin, MD; Catherine Small, MD; David Perlin, PhD; Thomas Walsh, MD, FIDSA
788
Factors Associated with Mortality in Carbapenem-Resistant Enterobacteriaceae Bacteremia: Focus on Antibiotic Therapy
Kelly E. Pillinger, PharmD; Seema Patel, PharmD; Allison Stilwell, BS; Danya Roshdy, PharmD; William Anderson, MS; Megan Templin, MS; Lewis Mccurdy, MD; Chris Polk, MD
789
Ceftolozane-tazobactam for the Treatment of Multi Drug Resistant Pseudomonas aeruginosa (MDRPA) Infections
Esther Molnar, MD; Emily Heil, PharmD, BCPS-AQID; Kimberly Claeys, PharmD, BCPS; Jon Hiles, PharmD; Jason Gallagher, PharmD, FCCP, FIDSA, BCPS
790
Treatment of Carbapenem-Resistant Enterobacteriaceae Infections with Ceftazidime-Avibactam
Elham Rahmati, M.D.; Emily Blodget, M.D.; Rosemary C. She, M.D.; Jennifer Cupo Abbott, PharmD; Robert A. Bonomo, MD; Brad Spellberg, M.D.
Posters
  • IDweek 2017 Poster.pdf (429.9 kB)
  • 791
    Health Outcomes from Multi-Drug Resistant Salmonella Infections in High-Income Countries: A Systematic Review and Meta-Analysis
    Andrea Parisi, MBBS; John A. Crump, FIDSA; Martyn Kirk, PhD; Kathryn Glass, PhD; Benjamin Howden, MBBS FRACP FRCPA PhD; Darren Gray, PhD; Luis Furuya-Kanamori, MBBS, MEpi, MPH; Samantha Vilkins, BSc
    794
    Retrospective Study of Linezolid versus Daptomycin for the Treatment of Vancomycin- Resistant Enterococcal Bloodstream Infection 
    Rena Rai, PharmD Candidate 2019; Parth Vaidya, PharmD Candidate 2020; Avani Desai, MD; Tanaya Bhowmick, MD; Melvin Weinstein, MD; Navaneeth Narayanan, PharmD, BCPS
    795
    Mortality Impact of CLSI Carbapenem Breakpoint Changes in Enterobacteriaceae Bloodstream Infections: a Patient-level Analysis of Published Data
    J Nicholas O'Donnell, PharmD, MSc; Nathaniel Rhodes, PharmD, MSc; Lauren R Biehle, PharmD; Twisha Patel, PharmD; Milena McLaughlin, PharmD, MSc, BCPS-AQ ID, AAHIVP; John Esterly, PharmD; Elizabeth B. Hirsch, PharmD, BCPS
    797
    Real World Analysis of Prescribing Patterns and Susceptibility of Ceftolozane/Tazobactam (C/T) Treatment using an Electronic Medical Record (EMR) Database in the United States
    Jason M. Pogue, PharmD; Laura Puzniak, PhD, MPH; Sanjay Merchant, PhD; Rahul Sanagaram, MBA , B.E; Elizabeth Rhee, MD
    799
    Epidemiologic Patterns and Clinical Implications of Genotypic Resistance Mechanism for Carbapenem-Resistant Enterobacteriaceae (CRE)Surveillance Isolates from Los Angeles County
    Sandeep Bhaurla, MPH, CIC; James A. Mckinnell, MD; Patricia Marquez, MPH, CIC; Marcelo Moran, MA, MPH; Audrey Manalo, PHM, M(ASCP)CM; Nicole Green, PhD, D(ABMM); Sean Buono, PHM; John Diaz-Decaro, MS; Julio Ramirez, PHM; Crystal Cadavid, RN, MSN, CMSRN, CIC; Alicia Pucci, RN, BSN, PHN; Merle Baron, RN, BSN, PHN; Talar Kamali, RN, MSN, PHN; Juliet Bugante, RN, BSN, PHN; Lindsey Pandes, MPH; Dawn Terashita, MD, MPH; Benjamin Schwartz, MD
    800
    Improving definitive therapy among patients with Methicillin-resistant Staphylococcus aureus bloodstream infections: Predictors of early therapeutic switch to linezolid or daptomycin
    Marin Schweizer, PhD; Kelly Richardson, PhD; Mary Vaughan Sarrazin, PhD; Michael Jones, PhD; Daniel Livorsi, MD, MSc; Rajeshwari Nair, PhD, MBBS, MPH; Michihiko Goto, MD, MSCI; Bruce Alexander, PharmD; Brice Beck, MA; Eli Perencevich, MD, MS, FIDSA, FSHEA
    801
    The Clinical Impact of Daptomycin Non-susceptible Enterococcus Bacteremia in Hematologic Malignancy
    Rachael A. Lee, MD; Keith S. Kaye, MD, MPH; Gary Cutter, PhD; Bernard Camins, MD, MSc
    Posters
  • DNSE poster PDF.pdf (828.8 kB)
  • 802
    Evaluation of telavancin dose capping in a large community hospital
    Ali Hassoun, MD FIDSA FACP; Jonathan Edwards, PharmD, BCPS AQ-ID
    Posters
  • Poster_Telavancin.pdf (756.7 kB)
  • CME Credits: Maximum of 0.00 hours of AMA PRA Category 1 Credit™


    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.